183 related articles for article (PubMed ID: 15513918)
21. Plasmodium falciparum PF10_0164 (ETRAMP10.3) is an essential parasitophorous vacuole and exported protein in blood stages.
Mackellar DC; O'Neill MT; Aly AS; Sacci JB; Cowman AF; Kappe SH
Eukaryot Cell; 2010 May; 9(5):784-94. PubMed ID: 20228203
[TBL] [Abstract][Full Text] [Related]
22. Characterization of the autophagy marker protein Atg8 reveals atypical features of autophagy in Plasmodium falciparum.
Navale R; Atul ; Allanki AD; Sijwali PS
PLoS One; 2014; 9(11):e113220. PubMed ID: 25426852
[TBL] [Abstract][Full Text] [Related]
23. Plasmodium falciparum: differential sensitivity in vitro to E-64 (cysteine protease inhibitor) and Pepstatin A (aspartyl protease inhibitor).
Bailly E; Jambou R; Savel J; Jaureguiberry G
J Protozool; 1992; 39(5):593-9. PubMed ID: 1522541
[TBL] [Abstract][Full Text] [Related]
24. Reduced glycerol incorporation into phospholipids contributes to impaired intra-erythrocytic growth of glycerol kinase knockout Plasmodium falciparum parasites.
Naidoo K; Coetzer TL
Biochim Biophys Acta; 2013 Nov; 1830(11):5326-34. PubMed ID: 23954205
[TBL] [Abstract][Full Text] [Related]
25. Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites.
Rosenthal PJ
Exp Parasitol; 1995 Mar; 80(2):272-81. PubMed ID: 7895837
[TBL] [Abstract][Full Text] [Related]
26. Antimalarial effects of human immunodeficiency virus type 1 protease inhibitors differ from those of the aspartic protease inhibitor pepstatin.
Parikh S; Liu J; Sijwali P; Gut J; Goldberg DE; Rosenthal PJ
Antimicrob Agents Chemother; 2006 Jun; 50(6):2207-9. PubMed ID: 16723585
[TBL] [Abstract][Full Text] [Related]
27. Gene disruption confirms a critical role for the cysteine protease falcipain-2 in hemoglobin hydrolysis by Plasmodium falciparum.
Sijwali PS; Rosenthal PJ
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4384-9. PubMed ID: 15070727
[TBL] [Abstract][Full Text] [Related]
28. Plasmodium falciparum ensures its amino acid supply with multiple acquisition pathways and redundant proteolytic enzyme systems.
Liu J; Istvan ES; Gluzman IY; Gross J; Goldberg DE
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8840-5. PubMed ID: 16731623
[TBL] [Abstract][Full Text] [Related]
29. Recombinant expression and enzymatic subsite characterization of plasmepsin 4 from the four Plasmodium species infecting man.
Li T; Yowell CA; Beyer BB; Hung SH; Westling J; Lam MT; Dunn BM; Dame JB
Mol Biochem Parasitol; 2004 May; 135(1):101-9. PubMed ID: 15287591
[TBL] [Abstract][Full Text] [Related]
30. Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum.
Asojo OA; Gulnik SV; Afonina E; Yu B; Ellman JA; Haque TS; Silva AM
J Mol Biol; 2003 Mar; 327(1):173-81. PubMed ID: 12614616
[TBL] [Abstract][Full Text] [Related]
31. Flap flexibility amongst plasmepsins I, II, III, IV, and V: Sequence, structural, and molecular dynamics analyses.
McGillewie L; Soliman ME
Proteins; 2015 Sep; 83(9):1693-705. PubMed ID: 26146842
[TBL] [Abstract][Full Text] [Related]
32. Studies on plasmepsins I and II from the malarial parasite Plasmodium falciparum and their exploitation as drug targets.
Moon RP; Bur D; Loetscher H; D'Arcy A; Tyas L; Oefner C; Grueninger-Leitch F; Mona D; Rupp K; Dorn A; Matile H; Certa U; Berry C; Kay J; Ridley RG
Adv Exp Med Biol; 1998; 436():397-406. PubMed ID: 9561248
[No Abstract] [Full Text] [Related]
33. A malarial cysteine proteinase is necessary for hemoglobin degradation by Plasmodium falciparum.
Rosenthal PJ; McKerrow JH; Aikawa M; Nagasawa H; Leech JH
J Clin Invest; 1988 Nov; 82(5):1560-6. PubMed ID: 3053784
[TBL] [Abstract][Full Text] [Related]
34. Azole-based non-peptidomimetic plasmepsin inhibitors.
Kinena L; Leitis G; Kanepe-Lapsa I; Bobrovs R; Jaudzems K; Ozola V; Suna E; Jirgensons A
Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800151. PubMed ID: 30063266
[TBL] [Abstract][Full Text] [Related]
35. Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1.
Sonoiki E; Nsanzabana C; Legac J; Sindhe KM; DeRisi J; Rosenthal PJ
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27821443
[TBL] [Abstract][Full Text] [Related]
36. Plasmepsins as potential targets for new antimalarial therapy.
Ersmark K; Samuelsson B; Hallberg A
Med Res Rev; 2006 Sep; 26(5):626-66. PubMed ID: 16838300
[TBL] [Abstract][Full Text] [Related]
37. Deciphering the mechanism of potent peptidomimetic inhibitors targeting plasmepsins - biochemical and structural insights.
Mishra V; Rathore I; Arekar A; Sthanam LK; Xiao H; Kiso Y; Sen S; Patankar S; Gustchina A; Hidaka K; Wlodawer A; Yada RY; Bhaumik P
FEBS J; 2018 Aug; 285(16):3077-3096. PubMed ID: 29943906
[TBL] [Abstract][Full Text] [Related]
38. Sequence homology and structural analysis of plasmepsin 4 isolated from Indian Plasmodium vivax isolates.
Rawat M; Vijay S; Gupta Y; Dixit R; Tiwari PK; Sharma A
Infect Genet Evol; 2011 Jul; 11(5):924-33. PubMed ID: 21382523
[TBL] [Abstract][Full Text] [Related]
39. Plasmodium falciparum responds to amino acid starvation by entering into a hibernatory state.
Babbitt SE; Altenhofen L; Cobbold SA; Istvan ES; Fennell C; Doerig C; Llinás M; Goldberg DE
Proc Natl Acad Sci U S A; 2012 Nov; 109(47):E3278-87. PubMed ID: 23112171
[TBL] [Abstract][Full Text] [Related]
40. Downstream effects of haemoglobinase inhibition in Plasmodium falciparum-infected erythrocytes.
Naughton JA; Nasizadeh S; Bell A
Mol Biochem Parasitol; 2010 Oct; 173(2):81-7. PubMed ID: 20478341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
